Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) has reported continued progress in intermediate-scale manufacturing and process development activities for key precursor components supporting ONC010, the company’s lead nanoparticle-formulated oncology candidate. The candidate is currently advancing through IND-enabling development, a critical phase before clinical trials can begin.
The work is being conducted with Dalton Pharma Services as part of Onco’s integrated chemistry, manufacturing and controls (CMC) strategy. The focus is on process optimization, analytical characterization, and manufacturing reproducibility to support future Good Manufacturing Practice (GMP) production, regulatory readiness, and planned first-in-human clinical development activities in Australia.
According to the company, the progress in manufacturing scale-up is essential for ensuring that ONC010 can be produced consistently and at sufficient quantities for clinical trials and eventual commercialization. The CMC strategy aims to de-risk the development pathway and streamline the transition from preclinical to clinical stages.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology that targets solid tumors.
The advancement of ONC010’s manufacturing process is a significant step toward bringing this potential therapy to patients. By optimizing the production of nanoparticle formulations, Onco-Innovations aims to improve the therapeutic index and delivery of oncology drugs, potentially offering new treatment options for solid tumors.
For more information about Onco-Innovations, visit https://oncoinnovations.com/. To view the full press release, see https://ibn.fm/Unt8n.
This news matters because it highlights the progress of a company developing innovative nanoparticle-based cancer therapies. The successful scale-up and manufacturing of ONC010 could accelerate its path to clinical trials, potentially offering a new treatment for solid tumors. Investors and the biomedical community should watch for further updates as the company moves toward regulatory filings and first-in-human studies.
